Glucagon-like peptide 1: a potential anti-inflammatory pathway in obesity-related asthma
Side effects - primarily gastrointestinal (nausea, vomiting, constipation, and abdominal discomfort) - are well-documented in clinical trial populations and are typically most pronounced during the initial titration phase before the body adapts to rising drug concentrations, which is why the standard-of-care approach involves gradual dose escalation over several weeks or months rather than starting at full therapeutic dose
Swissmedic is currently evaluating Eli Lillys pill orfoglipron
Why this matters for leaders and innovators: Its a moment where the mechanism of action is expanding: weight loss is important, but perhaps no longer sufficient to explain the full benefit
(While not all microdosing GLP-1 medications are compounded, it makes a difference in the cost and availability of the drug.) Contamination: The medication and needles can introduce contamination, bacteria, and other toxins into the body that can make you sick and cause infection
doi: 10.1016/j.jad.2024.10.062 22 McLaughlinA
